Randomized single-agents trials in recurrent epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 15, Issue 6 SUPPL. 3, 2005, Pages 247-251

  Sessa, Cristina ^a,c   Marsoni, S ^b  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^b Southern Europe New Drug Organization Foundation   (Italy)

^c OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Recurrent ovarian cancer; Second line single agent

Indexed keywords

DOXORUBICIN; PACLITAXEL; PLATINUM; TOPOTECAN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL; DEATH; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SELECTIVITY; HAND FOOT SYNDROME; HUMAN; MONOTHERAPY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; SURVIVAL RATE; TOXICITY; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TOPOTECAN;

EID: 30744444986     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00437.x     Document Type: Article

References (6)

1. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8:963-8.
2. Cannistra SA. Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?. J Clin Oncol 2002;20: 1158-60.
3. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15: 2183-93.
4. ten Bokkel Huinink W, Lane SR, Ross GA. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004;15:100-3.
5. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
6. Gordon AN, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1-8.